The State of the Microbiome

This report provides an assessment of how the pharmaceutical industry perceives the state of the microbiome, including the challenges associated with developing, launching, and manufacturing microbiome therapeutics as well as where opportunity remains to invest in the microbiome space.

Scope

GlobalData’s The State of the Microbiome provides in-house analyst expertise on the results of a 10 minutes survey of 158 GlobalData Pharma clients and prospects which was fielded from December 20, 2018 to January 7, 2019. Microbiome therapeutics were defined to include both live biotherapeutic products and products targeting the microbiome, excluding over the counter probiotics. Participants answered questions about the challenges they anticipate to impact the development, launch, manufacturing of microbiome therapeutics.

Components of the slide deck include:

  • Microbiome investment – determine level of activity and investment in the development of microbiome therapeutics by therapy area
  • Identify the challenges associated with:

o Developing microbiome therapeutics

o Launching microbiome therapeutics

o Manufacturing microbiome therapeutics

Reasons to buy

Develop and design your corporate strategies in the microbiome space by understanding the challenges associated with developing, launching and manufacturing microbiome therapeutics.

Develop business strategies by understanding the challenges associated with identifying and meeting regulatory requirments for the approval of microbiome therapeutics.

Identify where the opportunity remains to invest in the development of microbiome therapeutics.

Table of Contents

Table of Contents (PowerPoint Deck)

1 Study Design

1.1 Background, Objectives, and Design

1.2 Respondent Mix – Geography

1.3 Respondent Mix – Seniority Level and ...

Table of Contents (PowerPoint Deck)

1 Study Design

1.1 Background, Objectives, and Design

1.2 Respondent Mix – Geography

1.3 Respondent Mix – Seniority Level and Company Size

2 Executive Summary

2.1 Executive Summary

3 Microbiome Investment

3.1 Gastroenterology and Infectious Disease Mark the Most Active Therapy Areas

3.2 Infectious Disease and Gastroenterology Most Highly Invested Therapy Areas

3.3 A Closer Look at the Microbiome Pipeline

3.4 Microbiome Pipeline Targeting Gastrointestinal Indications and Infectious Diseases

3.5 A Closer Look at the Microbiome Pipeline Targeting Gastrointestinal Indications

3.6 A Closer Look at the Microbiome Pipeline Targeting Infectious Diseases

4 Challenges with Developing Microbiome Therapeutics

4.1 Identifying the Mechanism of Action Seen as a Major Challenge

4.2 Identifying the Mechanism of Action Is Seen as the Most Challenging Factor

4.3 A Closer Look by Seniority Level

5 Challenges with Launching Microbiome Therapeutics

5.1 Manufacturing Identified as a Major Challenge

5.2 Manufacturing Identified As the Most Challenging Factor

5.3 A Closer Look by Seniority Level

6 Challenges with Manufacturing Microbiome Therapeutics

6.1 Dose Formulation Is a Major Challenge

7 Key Findings and Recommendations

7.1 Summary of Key Findings

7.2 Recommendations

8 Appendix

8.1 Related Reports

8.2 Abbreviations

8.3 Primary Research

8.4 About the Authors

8.5 About Thematic Research

8.6 About GlobalData

8.7 Contact Us

8.8 Disclaimer

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports

This partnership has been great in refining our business model on which we have just been awarded half a million dollars at the biggest business competition in the world

  Pathovax